Position in ANIP
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$22,496,292
+$6,645,434 QoQ
Shares Held
271,760
+31.8% QoQ
Ownership
1.18%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#22
of 303 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANIP Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Aberdeen Group plc holds $220,070,795 across 11 Drug Manufacturers - Specialty & Generic names. ANIP ranks #4 (10.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
919,823 | $66,098,479 | |
| 2 | BCRX |
Biocryst Pharmaceuticals Inc
|
5,310,871 | $53,108,710 | |
| 3 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
403,485 | $25,802,865 | |
| 4 | ANIP |
Ani Pharmaceuticals Inc
This page
|
271,760 | $22,496,292 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
|
453,206 | $21,078,610 | |
| 6 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
737,670 | $13,248,553 | |
| 7 | ALKS |
Alkermes plc.
|
193,805 | $10,154,412 | |
| 8 | NBIX |
Neurocrine Biosciences Inc
|
22,955 | $3,868,835 |
All Filings in ANIP
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,496,292 | 271,760 | Shares | Defined | 2026-07-31 | |
| 2026-03-31 | $15,850,858 | 206,123 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $19,008,119 | 240,792 | Shares | Defined | 2026-01-16 | |
| 2025-09-30 | $24,702,504 | 269,678 | Shares | Defined | 2025-11-07 | |
| 2025-06-30 | $23,877,127 | 365,933 | Shares | Defined | 2025-07-24 | |
| 2025-03-31 | $28,058,677 | 419,099 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $13,154,705 | 237,965 | Shares | Defined | 2025-01-24 | |
| No filing history on record for this holder in this stock. | ||||||